2024-11-18 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Report

**1. Performance Comparison and Divergence:**

Intuitive Surgical Inc. (ISRG) is a company that manufactures and sells robotic-assisted surgery systems, including the da Vinci Surgical System.  Over the period analyzed, ISRG significantly outperformed the S&P 500 (VOO).  The cumulative return for ISRG is 325.08%, while the S&P 500's cumulative return is 123.86%. This results in a raw difference of 201.22%, placing the ISRG's performance at the 97.56th percentile of its historical performance relative to the S&P 500 (based on the provided min/max range).

The provided Alpha and Beta analysis shows consistently high alpha values (significantly above 1) across the analyzed periods, indicating substantial outperformance relative to the market benchmark. The beta values generally hover around 1.2-1.4, suggesting moderate sensitivity to overall market movements.  Market capitalization has steadily increased over time.  Note that MDD (Maximum Drawdown) values are relatively high, suggesting periods of significant price corrections.


**2. Recent Price Movement:**

* **Closing Price:** $527.61
* **5-Day Moving Average:** $534.98
* **20-Day Moving Average:** $519.84
* **60-Day Moving Average:** $496.47

The stock price is currently below its 5-day moving average, suggesting a short-term bearish trend, but above its 20-day and 60-day moving averages, indicating a potentially bullish longer-term trend.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 63.03 – This indicates the stock is neither overbought nor oversold, suggesting a relatively neutral momentum.
* **PPO (Percentage Price Oscillator):** 0.17 – A positive value suggests bullish momentum, but the magnitude is relatively small.
* **Delta_Previous_Relative_Divergence:** -2.44 –  Indicates a recent short-term downward trend in relative performance compared to the S&P 500.
* **Expected Return:** 2.28% – This represents the expected excess return over the S&P 500 for a long-term (2+ years) investment, suggesting continued outperformance, albeit at a lower rate than in the past.  The fact that the last price ($527.57) is close to but not significantly different from the 20-day moving average does not suggest a dramatic recent shift.

**4. Recent Financial Performance and Outlook:**

The provided financial data shows relatively consistent revenue and EPS growth, although there was a slight dip in the quarter ending September 2023.  While recent EPS and revenue numbers are slightly below the peak, they still show healthy growth compared to earlier years. Comparing the latest earnings to expectations would require access to the analyst consensus, which is not provided.


**5. Financial Information Analysis:**

The provided financial data (Revenue and Profitability, Capital and Profitability) shows relatively strong profitability margins (60-70%) and consistent revenue growth.  Return on Equity (ROE) fluctuates slightly but generally stays within a healthy range, though it has declined recently.


**6. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and Finbold.  Please provide links to any relevant news articles for a complete analysis.)*  A search of recent news would reveal any relevant earnings announcements, analyst upgrades or downgrades, and other market-moving events impacting ISRG's price.  Recent market outlook information from sources like Finbold should be included here.

**7. Summary of Analysis:**

ISRG has historically significantly outperformed the S&P 500, showing strong revenue and profitability.  However, recent relative performance has weakened slightly.  Technical indicators are neutral to mildly positive.  A long-term investment may still offer excess returns compared to the S&P 500, based on the projected 2.28% excess return, but this should be considered in context of the market outlook and potential risks.  Analysis of recent news and earnings releases (especially compared to analyst expectations) would be critical in confirming this outlook.  The company's relatively high MDD values highlight the risk of significant price corrections.


**8. Disclaimer:** This report is based on the limited data provided.  It should not be considered financial advice. Conducting thorough due diligence and seeking professional financial advice are crucial before making any investment decisions.  Access to real-time market data and news sources is necessary to complete a comprehensive analysis.
